Prescription drug · NDA
Icotyde (icotrokinra) NDC 57894-201
Icotrokinra 200 mg/1 · Tablet, Film coated · Oral · Janssen Biotech, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 57894-201-07 | 57894020107 | 1 BLISTER PACK in 1 CARTON (57894-201-07) / 7 TABLET, FILM COATED in 1 BLISTER PACK (57894-201-01)Marketed from Mar 17, 2026 | |
| 57894-201-30 | 57894020130 | 1 BOTTLE in 1 CARTON (57894-201-30) / 30 TABLET, FILM COATED in 1 BOTTLEMarketed from Mar 17, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Icotyde
- Generic name (nonproprietary)
- icotrokinra
- Active ingredients
- Icotrokinra — 200 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- Janssen Biotech, Inc.
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 220149
- Marketing start
- Listing expires
- Identifiers
- Product ID 57894-201_4d42efb1-d399-2a77-e063-6294a90af3ccSPL ID 4d42efb1-d399-2a77-e063-6294a90af3ccSPL set ID aee3c963-edc0-4252-8769-cdf6c7cdc21aRxCUI 2739036, 2739042UNII MUW8FP7HNZ
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N457894020107followed by a unit qualifier and the quantityPackage 57894-0201-07. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
ICOTYDE is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ICOTYDE is an interleukin-23 (IL-23) receptor antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. ( 1 )
Excerpt only. Read the full label for complete information.